Astellas may buy mitochondria start-up Mitokyne as part of R&D alliance
This article was originally published in Scrip
Astellas's new research partnership with the private US venture Mitokyne is in line with the Japanese firm's revised R&D strategy, under which it is making more use of external expertise and moving into new therapeutic areas.
You may also be interested in...
Astellas builds on a 2013 collaboration by acquiring Mitobridge. Ardelyx is partnering with Kyowa Hakko Kirin to bring tenapanor to market in Japan. Meanwhile, Depomed, Xoma and Bristol all offload programs before the end of the year.
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.
Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months.